SCHEMBL1015171

SCHEMBL1015171

O=C(COCC(=O)Nc1ccc(Cl)cc1C(=O)O)NCc1cccc(-c2ccco2)c1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SERPINE1 P05121 7/20 0.75
UBE2I P63279 2/20 0.48
CACNA1B Q00975 2/20 0.48
APBA1 Q02410 2/20 0.48
SAE1 Q9UBE0 2/20 0.48
UBA2 Q9UBT2 2/20 0.48
POLB P06746 2/20 0.48
G6PD P11413 1/20 0.48
MAPT P10636 2/20 0.45
PLA2G1B P04054 1/20 0.45
HTT P42858 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
ATG4B Q9Y4P1 1/20 0.45
LMNA P02545 2/20 0.45
THRB P10828 1/20 0.45
TSHR P16473 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HSD17B10 Q99714 1/20 0.43
KDM4E B2RXH2 1/20 0.43
GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1015337 0.91 SERPINE1 (0.62) SERPINE1UBE2ICACNA1BAPBA1SAE1
SCHEMBL1014818 0.87 SERPINE1 (0.56) SERPINE1POLBG6PDMAPTLMNA
SCHEMBL1016073 0.86 SERPINE1 (0.72) SERPINE1POLBTHRBTSHRSMN1; SMN2
SCHEMBL1014985 0.85 SERPINE1 (1.00) SERPINE1POLBG6PDMAPTPLA2G1B
SCHEMBL20814652 0.84 SERPINE1 (0.54) SERPINE1UBE2ICACNA1BAPBA1SAE1
SCHEMBL419303 0.83 SERPINE1 (0.74) SERPINE1POLBG6PDMAPTL3MBTL1
SCHEMBL1015582 0.82 SERPINE1 (0.69) SERPINE1POLBG6PDMAPTPLA2G1B
SCHEMBL1016045 0.82 SERPINE1 (0.69) SERPINE1POLBG6PDMAPTPLA2G1B
SCHEMBL1013725 0.82 SERPINE1 (0.72) SERPINE1POLBG6PDMAPTPLA2G1B
SCHEMBL1015937 0.80 SERPINE1 (0.67) SERPINE1POLBG6PDMAPTPLA2G1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8415479-B2 Inhibitor of plasminogen activator inhibitor-1 RENASCIENCE CO., LTD. (JP) 2013-04-09 US claimed
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 RENASCIENCE CO., LTD. (JP) 2011-05-12 US claimed
EP-2272822-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 Renascience CO., LTD. (JP) 2011-01-12 EP claimed
US-10092537-B2 Use for PAI-1 inhibitor RENASCIENCE CO., LTD. (JP) 2018-10-09 US disclosed
US-20160158188-A1 NOVEL USE FOR PAI-1 INHIBITOR RENASCIENCE CO., LTD. (JP) 2016-06-09 US disclosed
EP-2990057-A1 NOVEL USE FOR PAI-1 INHIBITOR Renascience Co., Ltd. (JP) 2016-03-02 EP disclosed
US-8415479-B2 Inhibitor of plasminogen activator inhibitor-1 RENASCIENCE CO., LTD. (JP) 2013-04-09 US disclosed
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 RENASCIENCE CO., LTD. (JP) 2011-05-12 US disclosed
EP-2272822-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 Renascience CO., LTD. (JP) 2011-01-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 SERPINE1, SERPINB1, SERPINC1 SERPINE1 1/4885UBE2I 2656/4885CACNA1B 4702/4885
US-20160158188-A1 NOVEL USE FOR PAI-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 SERPINE1 1/4885UBE2I 2517/4885CACNA1B 4651/4885
US-10092537-B2 Use for PAI-1 inhibitor SERPINE1, SERPINC1, SERPINB1 SERPINE1 1/4885UBE2I 2721/4885CACNA1B 4625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.